Linking resistin, inflammation, and cardiometabolic diseases

Article information

Korean J Intern Med. 2017;32(2):239-247

Publication date (electronic) : 2017 February 16

doi : https://doi.org/10.3904/kjim.2016.229

Hyeong Kyu Park ¹, Mi Kyung Kwak ¹, Hye Jeong Kim ¹, Rexford S. Ahima ²

¹Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea

²Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence to Rexford S. Ahima, M.D. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 3rd Floor, #333, 1830 East Monument St, Baltimore, MD 21287, USA Tel: +1-443-287-4719 Fax: +1-410-367-2042 E-mail: ahima@jhmi.edu

Received 2016 July 15; Accepted 2017 February 8.

Abstract

Adipose tissue secretes a variety of bioactive substances that are associated with chronic inflammation, insulin resistance, and an increased risk of type 2 diabetes mellitus. While resistin was first known as an adipocyte-secreted hormone (adipokine) linked to obesity and insulin resistance in rodents, it is predominantly expressed and secreted by macrophages in humans. Epidemiological and genetic studies indicate that increased resistin levels are associated with the development of insulin resistance, diabetes, and cardiovascular disease. Resistin also appears to mediate the pathogenesis of atherosclerosis by promoting endothelial dysfunction, vascular smooth muscle cell proliferation, arterial inflammation, and the formation of foam cells. Thus, resistin is predictive of atherosclerosis and poor clinical outcomes in patients with cardiovascular disease and heart failure. Furthermore, recent evidence suggests that resistin is associated with atherogenic dyslipidemia and hypertension. The present review will focus on the role of human resistin in the pathogeneses of inflammation and obesity-related diseases.

Keywords: Cardiovascular diseases; Inf lammation; Obesity; Resistin; Diabetes mellitus, type 2

INTRODUCTON

The metabolic complications of obesity include increased risks of type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVDs), sleep apnea, cancer, fatty liver, and other diseases. It is evident that obesity promotes a state of chronic inflammation in white adipose tissue (WAT), which, in turn, leads to insulin resistance. Adipose tissues secrete adipokines that play major roles in metabolism, immunity, and inflammation. Resistin is primarily secreted by adipocytes in rodents and was initially proposed as a link between obesity and insulin resistance [1]. In humans, however, resistin is mainly secreted by macrophages [2], which suggests that resistin is linked to inflammation. Recently, obesity, T2DM, and CVD have been recognized as chronic inflammatory disorders that may be connected to proinflammatory cytokines and various adipokines, including resistin. Thus, the present review will discuss the biology of resistin in rodents and humans with a focus on the evolving roles that resistin plays in inflammation and obesity-related diseases such as atherosclerosis, CVD, atherogenic dyslipidemia, and hypertension in humans.

RESISTIN IN RODENTS AND HUMANS

Resistin was initially identified in murine white adipocytes and is characterized by the presence of 10 to 11 cysteine residues [3]. The expression patterns of resistin in rodents and humans differ considerably. While murine resistin is expressed primarily by adipocytes, human resistin is predominantly expressed by peripheral blood mononuclear cells (PBMC) and macrophages [2]. The lack of resistin expression in human adipocytes may be due to the absence of a genomic binding site for nuclear receptor peroxisome proliferator-activated receptor γ, which normally controls the expression of the resistin gene (retn) in mouse adipocytes [4]. Human resistin shares only 59% of the sequence homology of murine resistin at the amino acid level and the resistin genes in rodents and humans have markedly divergent promoter regions, which suggests that there are differences in regulation and function. Resistin expression in mouse adipocytes is stimulated by high glucose levels but suppressed by tumor necrosis factor α (TNF-α) while human resistin is robustly induced by various inflammatory stimuli, including lipopolysaccharide (LPS), TNF-α, interleukin 6 (IL-6), IL-1β, and resistin itself, in PBMC and macrophages [5].

There are heightened circulating resistin levels in diet-induced obese and ob/ob mice but decreased levels following rosiglitazone treatment [1]. As in rodents, thiazolidinedione treatment downregulates the expression of human resistin in macrophages and reduces serum resistin levels. In mice, circulating resistin exists in a disulfide-linked hexamer or a smaller trimer that exhibits greater bioactivity under conditions of lowered hepatic insulin sensitivity. In humans, resistin circulates in trimeric and oligomeric forms of which the oligomeric form appears to have a more potent effect on the stimulation of proinflammatory cytokines [6]. Interestingly, the bioactivity of resistin is augmented by a physical interaction between resistin and heparanase [7].

ROLE OF MURINE RESISTIN IN INSULIN RESISTANCE

Resistin is a mediator of insulin resistance in rodents. For example, circulating resistin levels are elevated in obese mice and the administration of recombinant resistin impairs insulin action in normal mice. The central and peripheral administration of recombinant resistin and the transgenic overexpression of resistin induce hepatic insulin resistance in mice and, similarly, a variety of cells and tissues in rodents are responsive to resistin. The treatment of 3T3-L1 adipocytes, murine cardiomyocytes, and cultured skeletal muscle cells with murine resistin decreases insulin-stimulated glucose uptake into the cells [8] and resistin induces hepatic insulin resistance in primary rat hepatocytes and a mouse model with a high liver-specific expression of resistin [9]. Conversely, the neutralization of resistin with anti-resistin antibodies improves insulin sensitivity in diet-induced obese mice and the knockdown or deletion of resistin increases hepatic insulin sensitivity in mice on a high-fat diet [5].

The precise mechanisms by which murine resistin exerts its biological effects are not yet fully understood because the resistin receptor has yet to be characterized. However, recent studies have provided several potential candidates for the murine resistin receptor, including an isoform of decorin known as tyrosine kinase-like orphan receptor-1 (ROR1). Similarly, it has been proposed that a cleavage product of decorin, which is known as δ-decorin and lacks a glycanation site, is a functional receptor of murine resistin in adipose progenitor cells [10]. In fact, δ-decorin, as a functional resistin receptor, may regulate WAT expansion by modulating cell proliferation and migration as well as adipocyte differentiation in mice. Additionally, it has been shown that the interaction of mouse resistin with ROR1 results in the inhibition of ROR1 phosphorylation, which modulates the phosphorylation of extracellular signal-regulated kinases (ERKs) 1/2 and regulates the expression of suppressor of cytokine signaling 3 (SOCS3) and glucose transporter 4 in 3T3-L1 preadipocytes [11].

Murine resistin also decreases the phosphorylation of 5’ adenosine monophosphate-activated protein kinase (AMPK) in the liver, skeletal muscle, and WAT [12,13] while the inhibition of resistin leads to an increase in the phosphorylation of AMPK [14]. Furthermore, resistin interferes with multiple steps of the insulin signaling cascade, including the phosphorylation of insulin receptor substrates and the activations of phosphatidylinositol-3-kinase and protein kinase B/Akt in the rodent liver, muscle, and WAT [13-15]. Resistin treatment in rodents also induces the expression of SOCS3, which is a known inhibitor of insulin signaling, in the liver, muscle, and WAT [15]. Despite differences in the mechanisms of action underlying the effects of resistin in rodents and humans, the evidence indicates that murine resistin is linked to insulin resistance and has led to advances in research aimed at understanding the biology of human resistin.

ROLE OF HUMAN RESISTIN IN INFLAMMATION

Human resistin plays a major regulatory role in the inflammatory response [16] during which macrophages, PBMC, and vascular cells are the primary targets of resistin [17]. Resistin upregulates the expression of proinflammatory cytokines such as TNF-α, IL-6, IL-12, and monocyte chemoattractant protein (MCP)-1 in PBMCs, macrophages, and hepatic stellate cells via the nuclear factor-κB (NF-κB) pathway [18]. Resistin expression has also been identified in the non-adipocyte stromal vascular fraction of WAT, fibrotic livers, and atherosclerotic lesions [19]. Moreover, circulating resistin levels are correlated with inflammatory and fibrinolytic markers such as C-reactive protein (CRP), TNF-α, and IL-6 in in the general population and in individuals with T2DM, coronary atherosclerosis, chronic kidney disease, rheumatoid arthritis, and/or sepsis [6]. Plasma resistin levels are also related to disease severity in patients with severe sepsis or acute pancreatitis and are predictive of worse outcomes in non-septic but critically ill patients [5].

ROLE OF HUMAN RESISTIN IN ATHEROSCLEROSIS

In endothelial cells, human resistin increases the expressions of various proinflammatory factors, including MCP-1, endothelin-1, and matrix metalloproteinases, as well as adhesion molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin [20,21]. Human resistin also increases the proliferation and migration of human endothelial cells and vascular smooth muscle cells (VSMC) and increases endothelial permeability, which promotes endothelial cell/monocyte adhesion and infiltration [22]; these actions are mediated by the ERK and p38 mitogen-activated protein kinase signaling pathways [20]. Furthermore, resistin inhibits endothelial nitric oxide synthase via oxidative stress in human endothelial cells [23], promotes foam cell formation in human macrophages, induces a prothrombotic phenotype in human endothelial cells [17], and induces platelet activation by increasing P-selectin expression [24]. Taken together, these findings suggest that human resistin might play an important regulatory role in the modulation of interactions between endothelial cells, monocytes/macrophages, and VSMC in the pathogenesis and progression of atherosclerosis [25].

ROLE OF HUMAN RESISTIN IN INSULIN RESISTANCE

Given the association between murine resistin and insulin resistance, numerous clinical studies have examined the relationship between circulating resistin levels and insulin resistance in obese people with and without diabetes [6]. While some studies have shown positive correlations between resistin and insulin resistance, other studies have failed to identify significant changes in resistin levels in patients with insulin resistance and/or T2DM [8,25]. However, these discrepancies may be attributed to small sample sizes, population differences, disease status, and the use of non-standardized assays for measuring resistin [26].

To investigate the hypothesis that human resistin contributes to insulin resistance, Qatanani et al. [27] produced a ‘humanized resistin’ transgenic mouse model in which human resistin is primarily expressed in PBMC and macrophages but murine resistin is lacking. When these transgenic mice were fed a high-fat diet, they developed WAT inflammation and insulin resistance in the muscle and adipose tissues, which suggests that human resistin may be a link between the inflammatory environment and insulin resistance [27]. However, in this transgenic mouse model, the expression of human resistin in macrophages was constitutive and not induced by inflammatory stimuli. Therefore, it was unclear whether resistin induced by inflammatory signals could lead to insulin resistance in humans. To address this question, the Lazar laboratory generated a bacterial artificial chromosome transgenic mouse that lacked murine resistin but expressed human resistin, which was referred to as the Hum-Retn mouse [28]. Hum-Retn mice exhibit serum resistin levels similar to the normal range for humans. Additionally, in contrast to the earlier macrophage-driven resistin transgenic mice, human resistin levels in Hum-Retn mice show a marked increase in response to LPS treatment, which is also similar to humans [28]. Moreover, under conditions of chronic endotoxemia, Hum-Retn mice develop hepatic insulin resistance that is accompanied by inflammation in the liver and skeletal muscle, which supports the idea that resistin is involved in the pathophysiology of inflammation-induced insulin resistance in humans [28].

In line with this observation, it has been shown that human resistin inhibits insulin-stimulated glucose uptake in isolated mouse cardiomyocytes [29]. Resistin also blunts insulin signaling in myocytes via the suppression of myogenesis and stimulation of the proliferation of myoblasts in C1C12 myotubes [30], and induces insulin resistance via AMPK-dependent and AMPK-independent mechanisms in HepG2 hepatocytes [31]. Recently, prospective case-control studies have found that individuals with elevated baseline levels of resistin have a significantly higher risk of developing T2DM, even after adjusting for other risk factors [5,32].

POTENTIAL CANDIDATES FOR THE HUMAN RESISTIN RECEPTOR

The human resistin receptor remains unknown but Toll-like receptor 4 (TLR4) and adenylyl cyclase-associated protein 1 (CAP1) have recently been proposed as a putative candidates [33,34]. TLR4 serves as a receptor for the proinflammatory effects of recombinant human resistin in human myeloid and epithelial cells [33]. Additionally, recent findings in rats have shown that the direct binding of human resistin to TLR4 in the hypothalamus results in the activation of proinflammatory pathways and insulin resistance, which indicates that TLR4 is a binding site for resistin [35]. CAP1 has also been proposed as the in vivo functional receptor for resistin in human monocytes [34]. Resistin binds directly to CAP1 in monocytes and upregulates cyclic adenosine monophosphate concentrations, protein kinase A activity, and the NF-κB-related transcription of inflammatory cytokines in human monocytes [34]. However, further investigations will be necessary to clarify the relevance of these identified receptors in light of the biological effects of resistin in a variety of metabolic processes.

CLINICAL IMPLICATIONS OF HUMAN RESISTIN IN CVD

An increasing amount of evidence indicates that resistin is associated with coronary and peripheral artery diseases, ischemic stroke, and congestive heart failure [36]. Elevated resistin levels are predictive of coronary atherosclerosis independently of CRP levels in asymptomatic individuals and resistin is a predictor of re-stenosis after coronary artery stenting and major adverse cardiovascular events in patients with coronary artery disease (CAD) [6]. Additionally, elevated resistin levels are an independent predictor of all-cause mortality in Korean patients with acute myocardial infarction [37]. A prospective longitudinal study found that resistin was the only predictor of reduced amputation-free survival in patients with diabetes undergoing lower extremity bypass surgery [36] while a recent analysis investigating T2DM patients of European ancestry from two cross-sectional and two prospective studies revealed that resistin predicts incident major cardiovascular events and all-cause mortality [38]. More recently, it was shown that resistin levels are associated with recurrent coronary events in patients after hospitalization for acute coronary syndrome [39] and an association between resistin and ischemic stroke has been identified in some studies [6]. Similarly, a cross-sectional study from Japan and two nested case-control studies from Europe and the United States demonstrated that resistin is significantly associated with ischemic stroke among healthy individuals [6]. Higher resistin levels are also associated with a poorer prognosis in patients with CAD or atherothrombotic stroke [6]. Taken together, the abovementioned clinical evidence suggests a role for resistin in atherosclerotic disease in humans.

Recent clinical studies have demonstrated that elevated serum resistin levels are associated with the development and severity of heart failure [5]. Likewise, large cohort studies have shown that high resistin is independently associated with new-onset heart failure and that resistin is predictive of adverse cardiac outcomes in patients with heart failure [6]. However, whether human resistin acts as an etiological factor in the development of heart failure remains uncertain. Murine resistin is upregulated in rat cardiomyocytes following mechanical stretch [40] and the overexpression of murine resistin decreases left ventricular contractility and promotes cardiac hypertrophy in rats [41]. Interestingly, pre-treatment with murine resistin protects the heart against ischemia/reperfusion injury in a mouse heart perfusion model [42]. In contrast, pre-conditioning with recombinant human resistin prior to ischemia impairs contractile recovery during reperfusion and stimulates cardiac TNF-α secretion in isolated rat hearts [43]. The role of human resistin in the development of cardiotoxicity has also been explored using Hum-Retn mice [44]. Doxorubicin-induced cardiotoxicity is enhanced in Hum-Retn mice with a 4-fold elevation in serum resistin levels, as compared to control mice that lack human resistin [44]. Moreover, a clinical study found that elevated resistin levels are associated with a decline in ejection fraction in women treated for breast cancer with anthracycline-containing chemotherapy [44].

GENETIC EVIDENCE FOR THE ROLES OF HUMAN RESISTIN IN INSULIN RESISTANCE AND ATHEROSCLEROSIS

Several single-nucleotide polymorphisms (SNPs) in the human resistin gene (RETN) have been associated with elevated resistin levels and up to two-thirds of the variation in serum resistin levels may be attributable to genetic factors [45]. However, the identified variants of the RETN gene are inconsistently related to insulin resistance and atherosclerosis. In a Japanese population, the –638 G>A, –420 C>G, and –358 G>A polymorphisms in the promoter region of the RETN gene are associated with resistin levels while the G/G genotype at SNP –420 in the RETN gene is associated with susceptibility to T2DM and has been correlated with the expression of resistin in monocytes [5,6]. An analysis of 2,078 Japanese subjects revealed that plasma resistin is associated with SNP –420 and is correlated with insulin resistance [46]. In another study of a Korean population, the –420G and –537A alleles were associated with increased resistin levels but not T2DM [47]. In a study investigating Chinese subjects, the presence of the –420G and +62A alleles predicted worse glucose tolerance at the 5-year follow-up assessment [48].

Although the –420G allele that is associated with high resistin levels appears to be related to the risk of diabetes in Asians, data from non-Asian populations are conflicting [5]. An Italian study showed that the presence of the –420 C/G SNP in the RETN gene is associated with increased obesity and metabolic syndrome while an analysis of the Framingham Offspring cohort found that the –420 C>G SNP is not associated with obesity or diabetes but, rather, that SNPs in the 3’ region of RETN are associated with resistin levels [5]. On the other hand, a study of obese Egyptian subjects found that both the –420 C>G and +299 G>A SNPs are significantly associated with resistin levels, obesity, and insulin resistance [49]. In a Chinese population, the –420 C/G SNP in the RETN gene was associated with an increased risk of CAD while some studies of European and Caucasian populations did not find an association between the –420 C/G SNP in the RETN gene and coronary atherosclerosis [6].

ROLE OF HUMAN RESISTIN IN ATHEROGENIC DYSLIPIDEMIA

A large population-based study found a strong positive correlation between circulating resistin levels and fasting serum triglyceride concentrations [50]. In Indian men, serum resistin levels are positively correlated with very low density lipoprotein (VLDL) cholesterol and triglyceride levels but negatively correlated with high density lipoprotein cholesterol levels [51]. In contrast, other studies have shown that resistin is inversely correlated with low density lipoprotein (LDL) cholesterol levels [52,53]. It has been suggested that resistin is positively correlated with atherogenic smaller and denser LDL subclasses in subjects with T2DM [54] and a recent study showed that the treatment of human hepatocytes with resistin potently stimulated the secretion of VLDL apolipoprotein B (apoB) and lipids as well as increased hepatocyte lipid content [55]. Conversely, the removal of serum resistin via immunoprecipitation reduces hepatocyte apoB production [55]. The mechanisms by which resistin increases human hepatocyte VLDL production include the stimulation of apoB100 synthesis and microsomal triglyceride transfer protein activity, the induction of de novo lipogenesis via the SREBP1 and SREBP2 pathways, and the enhancement of apoB100 stability [56].

Resistin increases proprotein convertase subtilisin/kexin type 9 (PCSK9) in human hepatocytes, which, in turn, downregulates the LDL receptor [57] by inducing its degradation [58]. Resistin produces a significant reduction in hepatocyte LDL receptor levels, which mediates its VLDL effects, by inducing cellular PCSK9 expression [55]. Resistin and PCSK9 share a structural homology in the cysteine-rich portion within the C-terminal domain and, thus, it is possible that resistin and PCSK9 form aggregation complexes to target the LDL receptor [59]. In a study investigating a Chinese cohort, plasma resistin levels were significantly related to PCSK9 levels in CAD patients with normal body weight [60]. Taken together, these results indicate that resistin stimulates hepatic VLDL production, increases hepatic lipogenesis, and suppresses LDL receptor levels via increases in hepatocyte PCSK9. Thus, resistin may be a potential target for the treatment of atherogenic dyslipidemia in obese individuals with insulin resistance.

ROLE OF HUMAN RESISTIN IN HYPERTENSION

The central administration of resistin increases renal and lumbar sympathetic nerve activity (SNA) but decreases SNA in brown adipose tissue in rats, which suggests that resistin may contribute to the increased muscle SNA and reduced energy expenditure that is observed in subjects with obesity and diabetes [61]. Although blood pressure in rats is not significantly affected by centrally administered resistin [61], some clinical studies have demonstrated that circulating resistin levels are associated with hypertension in humans [62]. A positive correlation between plasma resistin levels and blood pressure has been observed in subjects both with and without T2DM [63,64]. Plasma resistin levels are increased in the young healthy offspring of individuals with essential hypertension compared to the young healthy offspring of normotensives [65]. Moreover, it has been demonstrated that higher plasma resistin levels are associated with an increased risk for incident hypertension among women without diabetes or hypertension, which is indicative of the effects of resistin on blood pressure [66]. However, to date, the precise mechanisms by which resistin affects blood pressure remain unclear.

CONCLUSIONS

Resistin appears to be a link between obesity and insulin resistance in rodents, and studies of ‘humanized resistin’ transgenic mice have implicated human resistin in the development of inflammation and insulin resistance. Additionally, a growing body of evidence from epidemiological, genetic, and clinical studies indicates that human resistin is involved in the pathogeneses of inflammation, insulin resistance, atherosclerosis, hypertension, and atherogenic dyslipidemia (Fig. 1). Further work is necessary to identify the specific receptor for human resistin, which would lead to delineation of specific signaling pathways and aid in the clarification of the role of resistin in the pathogeneses and treatments of T2DM, dyslipidemia, and CVD.

Figure 1.

Roles of human resistin in pathophysiological conditions. Resistin is upregulated in response to proinflammatory cytokines, lipopolysaccharide (LPS) and genetic factors, and downregulated by thiazolidinediones (TZDs). Resistin is primarily upregulated and secreted from peripheral blood mononuclear cell (PBMC) and macrophages, and in turn, acts on these cells, robustly enhancing inflammation and causing insulin resistance through activation of nuclear factor-κB. Resistin plays an important role in the pathogenesis and progression of atherosclerosis by inducing vascular endothelial dysfunction, and increasing proliferation of vascular smooth muscle cell (VSMC), and foam cell transformation. Resistin directly affects the function of cardiomyocytes predisposing to myocardial injury. Resistin can target multiple cell types, promoting inflammation, insulin resistance, atherosclerosis, and heart disease. Resistin also stimulates hepatic very low density lipoprotein production and suppresses low density lipoprotein receptor by increasing PCSK9 (proprotein convertase subtilisin/kexin type 9), driving atherogenic dyslipidemia. Resistin may also increase blood pressure via activation of the sympathetic nerve system. HSC, hepatic stellate cell.

Notes

No potential conflict of interest relevant to this article was reported.

Acknowledgements

This work was supported by the Soonchunhyang University Research Fund. R.S.A. is supported by National Institutes of Health grant P01-DK049210, and Bloomberg Distinguished Professorship.

References

1. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.

2. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472–476.

3. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004;304:1154–1158.

4. Tomaru T, Steger DJ, Lefterova MI, Schupp M, Lazar MA. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins. J Biol Chem 2009;284:6116–6125.

5. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011;22:259–265.

6. Park HK, Ahima RS. Resistin in rodents and humans. Diabetes Metab J 2013;37:404–414.

7. Novick D, Barak S, Ilan N, Vlodavsky I. Heparanase interacts with resistin and augments its activity. PLoS One 2014;9e85944.

8. Lazar MA. Resistin- and obesity-associated metabolic diseases. Horm Metab Res 2007;39:710–716.

9. Song R, Wang X, Mao Y, et al. Resistin disrupts glycogen synthesis under high insulin and high glucose levels by down-regulating the hepatic levels of GSK3beta. Gene 2013;529:50–56.

10. Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 2011;9:74–86.

11. Sanchez-Solana B, Laborda J, Baladron V. Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol 2012;26:110–127.

12. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004;303:1195–1198.

13. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats. J Clin Invest 2004;114:224–231.

14. Muse ED, Obici S, Bhanot S, et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004;114:232–239.

15. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA. Activation of SOCS-3 by resistin. Mol Cell Biol 2005;25:1569–1575.

16. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009;133:157–170.

17. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012;165:622–632.

18. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789–5795.

19. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006;69:76–85.

20. Hsu WY, Chao YW, Tsai YL, et al. Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. J Cell Physiol 2011;226:2181–2188.

21. Manduteanu I, Pirvulescu M, Gan AM, et al. Similar effects of resistin and high glucose on P-selectin and fractalkine expression and monocyte adhesion in human endothelial cells. Biochem Biophys Res Commun 2010;391:1443–1448.

22. Jamaluddin MS, Yan S, Lu J, Liang Z, Yao Q, Chen C. Resistin increases monolayer permeability of human coronary artery endothelial cells. PLoS One 2013;8e84576.

23. Chen C, Jiang J, Lu JM, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010;299:H193–H201.

24. Qiu W, Chen N, Zhang Q, et al. Resistin increases platelet P-selectin levels via p38 MAPK signal pathway. Diab Vasc Dis Res 2014;11:121–124.

25. Codoner-Franch P, Alonso-Iglesias E. Resistin: insulin resistance to malignancy. Clin Chim Acta 2015;438:46–54.

26. Huang X, Yang Z. Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest 2016;39:607–615.

27. Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009;119:531–539.

28. Park HK, Qatanani M, Briggs ER, Ahima RS, Lazar MA. Inflammatory induction of human resistin causes insulin resistance in endotoxemic mice. Diabetes 2011;60:775–783.

29. Graveleau C, Zaha VG, Mohajer A, et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 2005;280:31679–31685.

30. Sheng CH, Du ZW, Song Y, et al. Human resistin inhibits myogenic differentiation and induces insulin resistance in myocytes. Biomed Res Int 2013;2013:804632.

31. Luo Z, Zhang Y, Li F, et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. Endocrine 2009;36:60–69.

32. Chen BH, Song Y, Ding EL, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009;32:329–334.

33. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010;14(6B):1419–1431.

34. Lee S, Lee HC, Kwon YW, et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 2014;19:484–497.

35. Benomar Y, Gertler A, De Lacy P, et al. Central resistin overexposure induces insulin resistance through Tolllike receptor 4. Diabetes 2013;62:102–114.

36. Ding Q, White SP, Ling C, Zhou W. Resistin and cardiovascular disease. Trends Cardiovasc Med 2011;21:20–27.

37. Lee SH, Ha JW, Kim JS, et al. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coron Artery Dis 2009;20:33–39.

38. Menzaghi C, Bacci S, Salvemini L, et al. Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS One 2014;8e64729.

39. Khera AV, Qamar A, Murphy SA, Cannon CP, Sabatine MS, Rader DJ. On-statin resistin, leptin, and risk of recurrent coronary events after hospitalization for an acute coronary syndrome (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 study). Am J Cardiol 2015;116:694–698.

40. Wang BW, Hung HF, Chang H, Kuan P, Shyu KG. Mechanical stretch enhances the expression of resistin gene in cultured cardiomyocytes via tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 2007;293:H2305–H2312.

41. Chemaly ER, Hadri L, Zhang S, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol 2011;51:144–155.

42. Gao J, Chang Chua C, Chen Z, et al. Resistin, an adipocytokine, offers protection against acute myocardial infarction. J Mol Cell Cardiol 2007;43:601–609.

43. Rothwell SE, Richards AM, Pemberton CJ. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun 2006;349:400–407.

44. Schwartz DR, Briggs ER, Qatanani M, et al. Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer. Endocrinology 2013;154:4206–4214.

45. Menzaghi C, Coco A, Salvemini L, et al. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. J Clin Endocrinol Metab 2006;91:2792–2795.

46. Osawa H, Tabara Y, Kawamoto R, et al. Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 2007;30:1501–1506.

47. Cho YM, Youn BS, Chung SS, et al. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 2004;47:559–565.

48. Xu JY, Sham PC, Xu A, et al. Resistin gene polymorphisms and progression of glycaemia in southern Chinese: a 5-year prospective study. Clin Endocrinol (Oxf ) 2007;66:211–217.

49. El-Shal AS, Pasha HF, Rashad NM. Association of resistin gene polymorphisms with insulin resistance in Egyptian obese patients. Gene 2013;515:233–238.

50. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007;156:279–284.

51. Singh AK, Tiwari S, Gupta A, Natu SM, Mittal B, Pant AB. Association of resistin with metabolic syndrome in Indian subjects. Metab Syndr Relat Disord 2012;10:286–291.

52. Owecki M, Nikisch E, Miczke A, Pupek-Musialik D, Sowinski J. Serum resistin is related to plasma HDL cholesterol and inversely correlated with LDL cholesterol in diabetic and obese humans. Neuro Endocrinol Lett 2010;31:673–678.

53. Cabrera de Leon A, Almeida Gonzalez D, Gonzalez Hernandez A, et al. Relationships between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J Atheroscler Thromb 2014;21:454–462.

54. Abate N, Sallam HS, Rizzo M, et al. Resistin: an inflammatory cytokine: role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des 2014;20:4961–4969.

55. Costandi J, Melone M, Zhao A, Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res 2011;108:727–742.

56. Rashid S, Kastelein JJ. PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia. Expert Rev Cardiovasc Ther 2013;11:1567–1577.

57. Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol 2012;59:1697–1705.

58. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50 Suppl:S172–S177.

59. Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A 2007;104:14604–14609.

60. Li S, Xu RX, Zhang Y, et al. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status. J Endocrinol Invest 2015;38:1291–1299.

61. Kosari S, Rathner JA, Chen F, Kosari S, Badoer E. Centrally administered resistin enhances sympathetic nerve activity to the hindlimb but attenuates the activity to brown adipose tissue. Endocrinology 2011;152:2626–2633.

62. Badoer E, Kosari S, Stebbing MJ. Resistin, an adipokine with non-generalized actions on sympathetic nerve activity. Front Physiol 2015;6:321.

63. Takata Y, Osawa H, Kurata M, et al. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008;51:534–539.

64. Thomopoulos C, Daskalaki M, Papazachou O, et al. Association of resistin and adiponectin with different clinical blood pressure phenotypes. J Hum Hypertens 2011;25:38–46.

65. Papadopoulos DP, Makris TK, Perrea D, et al. Adiponectin: insulin and resistin plasma levels in young healthy offspring of patients with essential hypertension. Blood Press 2008;17:50–54.

66. Zhang L, Curhan GC, Forman JP. Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol 2010;21:1185–1191.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.